Tetra Bio-Pharma plans to bring international marketing and development expertise to the table for a cannabinoid-derived oral capsule and a topical cream for joint pain and inflammation, both currently under development.
After concluding a development and commercialization agreement with Genacol Canada last week, the companies plan to tap into the $2.5-billion market for topical pain-relief products.
Under the terms of the agreement, Tetra Bio-Pharma will use its formulation and regulatory expertise, and its clinical trial data from its topical cannabinoid and encapsulated cannabis-oil trials, to create innovative products for Genacol.
The companies plan to launch the products in 2019, when they will be marketed throughout Genacol’s network in Canada.
The Genacol trademark is registered in 81 countries worldwide and the company’s sales network is active in over 40 countries.
The agreement “will command a great deal of exposure” for Tetra’s products, said Tetra Bio-Pharma interim CEO and chief scientific officer Dr. Guy Chamberland.
“Tetra is in the business of developing cannabinoid derived prescription and natural health products and this agreement will enable Tetra Bio-Pharma to expand the number of offerings to our patients,” he said.
Genacol president & CEO estimates that the products “will generate several millions of dollars in sales for Genacol in Canada.”
“The products that Tetra Bio-Pharma is developing and Genacol will promote and commercialize are expected to play an important role in the pain and inflammation market in Canada,” he said.
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.
The company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements.
Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Genacol Corporation Canada is a leader in the development and marketing of natural health products primarily related to the treatment of joint pain and the maintenance of joint health.
Its mission is to improve the quality of life of its customers by offering them a range of innovative natural products.
Building on its success in Canada, Genacol has also developed in recent years an international presence with Genacol brand products available in more than 40 countries, including Latin America, Europe, Asia, the Middle East, Africa and the United States. In addition, the Genacol trademark is registered in 81 countries worldwide.
The success of Genacol is based on its collagen manufactured using a proprietary process called “AminoLock® Sequential Technology”, which is an ingredient in many of Genacol’s products.